January 18, 2022 10:00 AM ESTUpdated 10:29 AM
FDA+

With few re­main­ing un­ap­proved drugs, re­searchers tell FDA its Un­ap­proved Drugs Ini­tia­tive is no longer ef­fec­tive

Zachary Brennan

Senior Editor

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Anne Wo­j­ci­c­ki and Re­gen­eron set to duke it out in restart­ed 23andMe auc­tion

FDA's Prasad ex­plains ra­tio­nale be­hind paus­ing Val­neva's chikun­gun­ya vac­cine in se­niors

Biotech ranks as Chi­na’s best shot to sur­pass US in emerg­ing tech, re­port finds

A decade af­ter its ill-fat­ed $40.5B megadeal, Te­va piv­ots from gener­ics to in­no­va­tion

Re­gen­eron plans to buy 23andMe for $256M

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times